Pharmacogenomics Advisory Committee Being Formed By FDA To Oversee Data Submissions
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency expects to publish final pharmacogenomics guidance this summer, along with "companion documents" on the interdisciplinary PG review group and a standard process for voluntary PG data submissions, FDA's Lesko tells DIA EuroMeeting in Prague.
You may also be interested in...
Biomarker Development Will Get Advisory Committee Review
FDA will seek advisory committee reviews of pharmacogenomic biomarkers as part of their development process
Biomarker Development Will Get Advisory Committee Review
FDA will seek advisory committee reviews of pharmacogenomic biomarkers as part of their development process
FDA Pharmacogenomics Guidance Will Be Finalized Later This Year
FDA will not be releasing its final guidance on pharmacogenomic data submissions until the second half of the year, CDER’s Galson tells BIO. The agency continues to review pharmacogenomic data submitted with product applications.